Synthesis and pharmacological properties of 3-(2-methyl-furan-3-yl)-4-substituted-Δ 2 - 1,2,4-triazoline-5-thiones

Central European Journal of Chemistry

Volumn 6, Issue 1, 2008, Pages 47-53

  Siwek, Agata ^a   Wujec, Monika ^a   Dobosz, Maria ^a   Jagiełło Wójtowicz, Ewa ^a   Chodkowska, Anna ^a   Kleinrok, Agnieszka ^a   Paneth, Piotr ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Wyzsza Szkola Humanistyczno Ekonomiczna w Lodzi   (Poland)

Author keywords

CNS activity; DFT; 2 1,2,4 triazoline 5 thione

Indexed keywords

EID: 85000259348     PISSN: 18951066     EISSN: 16443624     Source Type: Journal    
DOI: 10.2478/s11532-007-0058-0     Document Type: Article

References (38)

1. B. Modzelewska-Banachiewicz, J. Banachiewicz, A. Chodkowska, E. Jagiello-Wójtowicz, L. Mazur, Eur. J. Med. Chem. 39, 873 (2004)
2. X-Y. Sun et al., Arch. Pharm. Res. 29, 1080 (2006)
3. U. Misra, A. Hitkari, A.K. Saxena, S. Gurtu, K. Shanker, Eur. J. Med. Chem. 31, 629 (1996)
4. S.H.L. Chiu, S.E.W Huskey, Drug Metabol. Dispos. 26, 838 (1998)
5. B. Tozkoparan et al., Arzneimittelforschung 55, 533 (2005)
6. O.A. Al-Deeb et al., Arzneimittelforschung 56, 40 (2006)
7. B.S. Holla et al., Farmaco 56, 565 (2001)
8. H. Shivarama Holla, B. Sooryanarayana Rao, B.K. Sarojini, P.M. Akberali, N. Suchetha Kumari, Eur. J. Med. Chem. 41, 657 (2006)
9. G. Turan-Zitouni, Z.A. Kaplancikli, K. Erol, F.S. Kiliç, Il Farmaco 54, 218 (1999)
10. M. De La Rosa et al., Bioorg. Med. Chem. Lett. 16, 4444 (2006)
11. A.A. Ikizler, C.B. Johansson, O. Bekircan, C. Çelik, Acta Polon. Pharm.-Drug Research 56, 283 (1999)
12. S. Demirayak, K. Benkli, K. Güven, Eur. J. Med. Chem., 35, 1037 (2000)
13. X-P. Hui, L-M. Zhang, Z-Y. Zhang, Q. Wang, F. Wang, J. Chin. Chem. Soc., 47, 535 (2000)
14. Ch-H. Chu, X-P. Hui, Y. Zhang, Z-Y. Zhang, Z.-Ch.. Li, R.-A. Liao, J. Chin. Chem. Soc. 48, 121 (2001)
15. M. Wujec, M. Pitucha, M. Dobosz, U. Kosikowska, A. Malm, Acta Pharm. 54, 251 (2004)
16. E.B. Åkerblom, D.E.S. Campbell, Eur. J. Med. Chem. 16, 312 (1973)
17. F.C. Meotti et al., Environ. Toxicol. Pharmacol. 37, 37 (2003)
18. J. Malmström et al., J. Am. Chem. Soc. 123, 3434 (2001)
19. J.R. Boissier, J. Tardy, J.C. Diverres, Med. Exp. 3, 81 (1960)
20. C. Aron, P. Simon, C. Larousse, J.R. Boissier, Neuropharmacology 10, 459 (1971)
21. R.D. Porsolt, A. Bertin, M. Deniel, M. Jalfre, Arch. Int. Pharmacodyn. Thé. 229, 327 (1977)
22. L.B. Witkin, C.F. Heubner, E. O'Keete, P. Spitatalitta, A.J. Plummer, J. Pharmacol. Exp. Ther. 133, 400 (1961)
23. S.J. Corne, R.W. Pickering, B.T. Warner, Br. J. Pharmacol. 20, 106 (1963)
24. A.D. Becke, Phys. Rev. A 38, 3098 (1988)
25. A.D. Becke, J. Chem. Phys. 98, 5648 (1993)
26. J.P. Perdew et al., Phys. Rev. B 46, 13584 (1992)
27. P.C. Hariharan, J.A. Pople, Theor. Chim. Acta 28, 213 (1973)
28. M.M. Francl et al., J. Chem. Phys. 77, 3654 (1982)
29. M.J. Frisch et al., Gaussian 03 Revision D.01 Gaussian Inc, Wallingford CT (2004)
30. S. Miertus, E. Scrocco, J. Tomasi, J. Chem. Phys. 55, 117 (1981)
31. C.M. Breneman, K.B. Wiberg, J. Comp. Chem. 11, 361 (1990)
32. GaussView 3.09, Gaussian Inc., Pittsburg, PA, USA, (2003)
33. HyperChem 8.0.3, HyperCube Inc., Gainsville, FL, USA, (2007)
34. R.A. Kwiecień, A. Lewandowicz, P. Paneth, Chapter 7 In: J. Leszczyński (Ed.), Challenges and Advances in Computational Chemistry and Physics, W.A. Sokalski (Ed.), Vol. 4, Molecular Materials with Specific Interactions - Modeling and Design (Springer, Amsterdam, 2007), 341
35. V.L. Schramm, Acc. Chem. Res. 36, 588 (2003)
36. W.A. Carroll et al., Bioorg. Med. Chem. Lett. 17, 4044 (2007)
37. T. Akbarzadeh, S.A. Tabatabai, M.J. Khoshnoud, B. Shafaghic, A. Shafieea, Bioorg. Med. Chem. Lett. 11, 769 (2003) and references 7, 8 therein
38. G. Pastorin et al., J. Med. Chem. 46, 4287 (2003)